{ "company": "Guardant Health", "ticker": "GH", "period": { "from": "2026-02-26", "to": "2026-03-28", "days": 30 }, "sentiment_breakdown": { "positive": 35, "negative": 54, "neutral": 36 }, "synthesis": { "executive_summary": "**Executive Summary: Guardant Health (GH) Sentiment Analysis**\n\nDuring the period of February 26 to March 28, 2026, sentiment analysis for Guardant Health (GH) indicated a predominantly negative outlook. Out of 125 analyzed items, 43.2% were classified as negative, compared to 28% positive and 28.8% neutral. This overall negative sentiment was primarily driven by a higher volume of research publications and specific news items that, despite their apparent positive framing, were algorithmically categorized as negative by the sentiment model.\n\nKey positive developments included Guardant Health winning the Oncology Product Innovation of the Year at the Healthcare Asia Medtech Awards 2026 for its Shield™ Multi-cancer Detection test, recognized for its high specificity, sensitivity, and FDA Breakthrough Device Designation. Additionally, a strategic partnership with Verana Health to develop a real-world evidence platform for precision oncology was noted as a positive driver, aiming for high-margin, recurring revenue streams. Conversely, a significant negative event, as per the sentiment analysis, was the partnership with actor Patrick Dempsey to raise awareness for colorectal cancer screening using the Shield blood test. Despite its promotional nature, this event registered a strong negative sentiment score, contributing to the overall bearish trend.", "key_findings": [ "✓ Guardant Health wins at Healthcare Asia Medtech Awards 2026", "✓ Efficacy and safety of peptide radionuclide therapy with (177)Lu-DOTATATE in Japanese patients with advanced neuroendocrine neoplasm: a multicenter retrospective study (JON2203-N).", "✓ Implementing a successful patient navigation program for follow-up colonoscopy: Lessons from the PRECISE study.", "✗ Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration.", "✗ Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.", "✗ Impact of offering blood-based testing alongside existing modalities for colorectal cancer screening among those who previously declined screening: an economic evaluation." ], "overall_sentiment": "negative" }, "top_positive": [ { "title": "Guardant Health wins at Healthcare Asia Medtech Awards 2026", "date": "2026-03-27", "source": "alpha_vantage", "score": 0.772 }, { "title": "Efficacy and safety of peptide radionuclide therapy with (177)Lu-DOTATATE in Japanese patients with advanced neuroendocrine neoplasm: a multicenter retrospective study (JON2203-N).", "date": "2026 Mar 2", "source": "pubmed", "score": 0.586 }, { "title": "Implementing a successful patient navigation program for follow-up colonoscopy: Lessons from the PRECISE study.", "date": "2026-03-28", "source": "pubmed", "score": 0.586 }, { "title": "Verana and Guardant’s RWE Stack Aims to Solve Precision Oncology’s Data Challenges—Driving Growth Through Recurring Revenue and Broader Data Collections", "date": "2026-03-24", "source": "alpha_vantage", "score": 0.527 }, { "title": "Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars.", "date": "2026 Mar 7", "source": "pubmed", "score": 0.494 }, { "title": "Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI).", "date": "2026 Mar 6", "source": "pubmed", "score": 0.477 }, { "title": "Guardant Health (GH) awards 17,040 RSUs to Chief People Officer Monroe", "date": "2026-03-14", "source": "alpha_vantage", "score": 0.459 }, { "title": "After a year, I'm ready for critiques!", "date": "2026-03-15", "source": "reddit", "score": 0.42 }, { "title": "Guardant Health’s Shield Tour Links Rural Access And Growth Expectations", "date": "2026-03-07", "source": "alpha_vantage", "score": 0.382 }, { "title": "Guardant Health’s Shield Tour Links Rural Access And Growth Expectations", "date": "2026-03-07", "source": "alpha_vantage", "score": 0.382 } ], "top_negative": [ { "title": "Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.869 }, { "title": "Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.", "date": "2026 Mar 4", "source": "pubmed", "score": -0.869 }, { "title": "Impact of offering blood-based testing alongside existing modalities for colorectal cancer screening among those who previously declined screening: an economic evaluation.", "date": "2026-03-28", "source": "pubmed", "score": -0.86 }, { "title": "Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.823 }, { "title": "Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened", "date": "2026-03-07", "source": "alpha_vantage", "score": -0.791 }, { "title": "Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened", "date": "2026-03-03", "source": "reddit", "score": -0.791 }, { "title": "Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.751 }, { "title": "Middle East war begins – stocks drop – Update 03/09/26", "date": "2026-03-09", "source": "reddit", "score": -0.718 }, { "title": "Extreme fear grips the stock market – stock drop slows – Update 03/16/26", "date": "2026-03-16", "source": "reddit", "score": -0.68 }, { "title": "KMI partners with Guardant Health on liquid biopsy cancer screening", "date": "2026-03-12", "source": "alpha_vantage", "score": -0.66 } ], "raw_data": { "total_items": 125, "items": [ { "source": "alpha_vantage", "title": "Why Guardant Health (GH) Stock Is Falling Today", "url": "https://www.tradingview.com/news/stockstory:a4995f8d7094b:0-why-guardant-health-gh-stock-is-falling-today/", "date": "2026-03-27", "summary": "Guardant Health (GH) stock fell 3% today due to escalating uncertainty from the U.S.-Iran conflict and Trump administration policy deadlines, which also caused major indices to drop. This follows a 3.4% dip almost a month ago driven by higher-than-expected wholesale inflation data. Guardant Health's shares are highly volatile and have fallen 16.7% year-to-date, trading significantly below its 52-week high.", "sentiment_score": -0.42748, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "alpha_vantage", "title": "Guardant Health wins at Healthcare Asia Medtech Awards 2026", "url": "https://healthcareasiamagazine.com/co-written-partner/event-news/guardant-health-wins-healthcare-asia-medtech-awards-2026", "date": "2026-03-27", "summary": "Guardant Health Pte Ltd won the Oncology Product Innovation of the Year at the Healthcare Asia Medtech Awards 2026 for its ShieldTM Multi-cancer Detection (MCD) test. This blood test screens for 10 types of cancers, demonstrating 99% overall specificity and 74% sensitivity across six aggressive cancers in recent data. The Shield MCD test has also received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).", "sentiment_score": 0.402736, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.772, "confidence": 0.77 } }, { "source": "alpha_vantage", "title": "Tempus AI Reinforces Market Position With Collaborations in 2026", "url": "https://www.tradingview.com/news/zacks:5e5cf70e2094b:0-tempus-ai-reinforces-market-position-with-collaborations-in-2026/", "date": "2026-03-26", "summary": "Tempus AI (TEM) is strengthening its market position in 2026 through strategic collaborations with pharmaceutical companies, healthcare institutions, and technology innovators. These partnerships aim to improve clinical outcomes and accelerate drug development by leveraging Tempus's AI expertise and proprietary platforms. Notable collaborations include work with Daiichi Sankyo on an ADC program, Median Technologies for lung nodule characterization, Blood Cancer United for a pediatric AML registr", "sentiment_score": 0.028319, "sentiment_label": "Neutral", "relevance_score": 0.337413, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia", "url": "http://www.msn.com/en-us/health/other/guardant-health-gh-partners-with-manulife-to-launch-shield-multi-cancer-detection-test-in-asia/ar-AA1Z4xZA?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-03-25", "summary": "Guardant Health (GH) is partnering with Manulife to introduce its Shield multi-cancer detection test across Asia. This collaboration aims to provide enhanced cancer screening options in the region, leveraging Manulife's network to expand access to Guardant Health's diagnostic technology. The initiative represents a significant step in making advanced multi-cancer detection more widely available.", "sentiment_score": 0.432309, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health Ignites 5.6% Surge: A Volatile Breakout or a Trap for the Unwary?", "url": "https://www.bitget.com/news/detail/12560605304566", "date": "2026-03-25", "summary": "Guardant Health (GH) experienced a 5.63% intraday surge to $89.245, driven by a new partnership with Manulife, despite technical indicators like the RSI being deeply oversold. While the rally shows short-term bullish momentum and potential for breakout past the 30-day moving average, it faces resistance around the $90 psychological barrier and requires sustained movement above $95 to confirm a trend reversal. Options traders are targeting calls with high leverage and liquidity, signaling aggress", "sentiment_score": 0.342275, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.318, "confidence": 0.32 } }, { "source": "alpha_vantage", "title": "Verana and Guardant’s RWE Stack Aims to Solve Precision Oncology’s Data Challenges—Driving Growth Through Recurring Revenue and Broader Data Collections", "url": "https://www.bitget.com/amp/news/detail/12560605299239", "date": "2026-03-24", "summary": "Verana Health and Guardant Health are collaborating to build a robust real-world evidence (RWE) data platform to address precision oncology's data challenges. This partnership integrates Guardant's clinicogenomic datasets with COTA's AI-enhanced oncology data, acquired through Verana's merger, to provide comprehensive insights for drug development. The strategy focuses on high-margin, recurring revenue streams from companion diagnostics and expanding into new therapeutic areas like bladder and p", "sentiment_score": 0.016985, "sentiment_label": "Neutral", "relevance_score": 0.340235, "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } }, { "source": "alpha_vantage", "title": "Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data", "url": "https://www.prnewswire.com/news-releases/verana-health-and-guardant-health-partner-to-advance-precision-medicine-with-real-world-data-302719285.html", "date": "2026-03-24", "summary": "Verana Health and Guardant Health have partnered to combine their real-world data resources to accelerate precision medicine, particularly in oncology and urology. This collaboration will allow biopharmaceutical researchers to access curated EHR data alongside clinicogenomic testing data, enhancing the understanding of patient journeys and aiding therapy development. The combined data sets will help validate correlations between molecular biomarkers, treatment decisions, and clinical outcomes, a", "sentiment_score": 0.422029, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) Valuation Check As New Manulife Partnership Expands Shield Testing In Asia", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-valuation-check-as-new-manulife-partnersh", "date": "2026-03-23", "summary": "Guardant Health (GH) is under scrutiny after announcing a partnership with Manulife to expand its Shield multi-cancer detection blood test in Asia, starting April 2026. Despite recent share price volatility, the company has shown strong long-term momentum with an 84.77% one-year return, yet some models suggest it's significantly undervalued. The article debates whether the market has already factored in future growth, highlighting potential valuation risks from a high P/S ratio compared to the i", "sentiment_score": 0.257238, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.303, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia", "url": "https://www.msn.com/en-us/health/other/guardant-health-gh-partners-with-manulife-to-launch-shield-multi-cancer-detection-test-in-asia/ar-AA1Z4xZA", "date": "2026-03-22", "summary": "Guardant Health (GH) has partnered with Manulife to introduce its Shield multi-cancer detection test in Asia. This collaboration aims to provide early cancer detection solutions to a broader population in the region through Manulife's network. The Shield test is designed to detect multiple types of cancer at early stages, potentially improving patient outcomes.", "sentiment_score": 0.428177, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Why Guardant Health’s (GH) 2026 screening story reinforced Piper Sandler’s bullish view", "url": "https://www.msn.com/en-us/money/companies/why-guardant-health-s-gh-2026-screening-story-reinforced-piper-sandler-s-bullish-view/ar-AA1YTUKn?ocid=finance-verthp-feeds", "date": "2026-03-21", "summary": "This article discusses Piper Sandler's maintained bullish outlook on Guardant Health (GH), specifically reinforced by insights from the company's 2026 screening strategy. The analyst firm highlighted a conference presentation that detailed key upcoming milestones and reiterated confidence in Guardant Health's future growth prospects.", "sentiment_score": 0.827102, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia", "url": "https://www.msn.com/en-us/money/general/guardant-health-gh-partners-with-manulife-to-launch-shield-multi-cancer-detection-test-in-asia/ar-AA1Z4xZA", "date": "2026-03-21", "summary": "Guardant Health (GH) has partnered with Manulife to launch its Shield multi-cancer detection test in Asia. This collaboration aims to make the early cancer detection test accessible to a broader population in the region, leveraging Manulife's network. The Shield test is designed to detect multiple types of cancer from a single blood draw.", "sentiment_score": 0.4227, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Insider Sell: Musa Tariq Sells Shares of Guardant Health Inc (GH)", "url": "https://www.gurufocus.com/news/8728137/insider-sell-musa-tariq-sells-shares-of-guardant-health-inc-gh", "date": "2026-03-20", "summary": "Musa Tariq, a Director at Guardant Health Inc (GH), sold 348 shares of the company on March 18, 2026, bringing his total ownership to 8,394 shares. Over the past year, Tariq has sold a total of 4,489 shares with no purchases. Guardant Health Inc is considered significantly overvalued with a price-to-GF-Value ratio of 1.68, based on its trading price of $88.09 against a GF Value of $52.52.", "sentiment_score": -0.315807, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Insider Selling: Guardant Health (NASDAQ:GH) Director Sells 348 Shares of Stock", "url": "https://www.marketbeat.com/instant-alerts/insider-selling-guardant-health-nasdaqgh-director-sells-348-shares-of-stock-2026-03-19/", "date": "2026-03-19", "summary": "Guardant Health (NASDAQ:GH) Director Musa Tariq sold 348 shares of the company's stock on March 18, 2026, for a total value of $30,655.32. This sale reduced his stake by 3.98% to 8,394 shares. The company's stock traded up 2.1% to $89.08, and despite missing Q4 EPS estimates, revenue increased by 39.4% year-over-year.", "sentiment_score": -0.185501, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (NASDAQ: GH) director sells 348 company shares", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-426fc16d4cb8.html", "date": "2026-03-19", "summary": "Guardant Health director Tariq Musa sold 348 shares of the company's common stock on March 18, 2026, at an average price of $88.09 per share. This open-market transaction was reported via a Form 4 SEC filing. Following the sale, Musa directly holds 8,394 shares of Guardant Health stock.", "sentiment_score": -0.286525, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) director Tariq Musa sells $30,655 in stock", "url": "https://m.investing.com/news/insider-trading-news/guardant-health-gh-director-tariq-musa-sells-30655-in-stock-93CH-4571897?ampMode=1", "date": "2026-03-19", "summary": "Guardant Health (GH) director Tariq Musa sold 348 shares of common stock for $30,655 on March 18, 2026, bringing his total direct ownership to 8,394 shares. This insider sale occurs as the company's stock trades near $89.08. Separately, Guardant Health recently reported its Q4 2025 results, with several analysts reaffirming or increasing price targets due to strong performance and a positive outlook for commercial expansion and cost management.", "sentiment_score": 0.10422, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Cathie Wood’s ARK sells Guardant Health stock, buys Arcturus Therapeutics", "url": "https://www.investing.com/news/company-news/cathie-woods-ark-sells-guardant-health-stock-buys-arcturus-therapeutics-93CH-4569651", "date": "2026-03-19", "summary": "Cathie Wood's ARK sold 11,757 shares of Guardant Health (NASDAQ:GH) totaling over $1 million through its ARKG ETF, continuing a trend of reducing its position in the company. Concurrently, ARK purchased 33,864 shares of Arcturus Therapeutics Holdings (NASDAQ:ARCT) for $216,390, indicating a strategic shift towards innovative therapeutics. A smaller sale of Standard Biotools (NASDAQ:LAB) shares also occurred, reflecting ARK's ongoing portfolio reallocation within the biotech sector.", "sentiment_score": -0.427625, "sentiment_label": "Bearish", "relevance_score": 0.959537, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Director at Guardant Health (GH) receives 232 shares via RSUs", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-5d6041acaa59.html", "date": "2026-03-18", "summary": "Guardant Health director Manuel Hidalgo Medina received 232 common shares through the exercise of restricted stock units (RSUs) on March 17, 2026, as part of his equity compensation. These shares were converted at a price of $0.00 per share, increasing his direct holdings to 1,425 shares. The RSU award originated from a grant on July 17, 2024, with a four-year vesting schedule.", "sentiment_score": 0.028969, "sentiment_label": "Neutral", "relevance_score": 0.313073, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (NASDAQ: GH) Form 144 shows proposed insider sale of shares", "url": "https://www.stocktitan.net/sec-filings/GH/144-guardant-health-inc-sec-filing-295c113b5a16.html", "date": "2026-03-18", "summary": "Guardant Health (NASDAQ: GH) has filed a Form 144 indicating proposed insider sales of shares. The filing details planned dispositions of Common Stock linked to restricted stock lapses, with events scheduled for January 15, 2026 (250 shares) and February 15, 2026 (98 shares), handled by Charles Schwab & Co., Inc. This notice acts as a procedural disclosure of intent to sell rather than a record of completed transactions.", "sentiment_score": 0.039876, "sentiment_label": "Neutral", "relevance_score": 0.99808, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership", "url": "https://www.businesswire.com/news/home/20260316025112/en/Guardant-Health-Launches-Shield-Multi-Cancer-Detection-MCD-Test-in-Multiple-Markets-in-Asia-with-Manulife-Partnership", "date": "2026-03-18", "summary": "Guardant Health, Inc. announced the launch of its Shield multi-cancer detection (MCD) test in several Asian markets through a partnership with Manulife. This collaboration will provide eligible Manulife customers in Hong Kong, Singapore, and the Philippines access to the blood-based test, which screens for 10 common cancers, starting in April 2026. The initiative aims to improve early cancer detection and screening participation in a region where cancer remains a leading cause of death.", "sentiment_score": 0.437022, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026", "url": "https://www.biospace.com/press-releases/guardant-health-to-present-28-abstracts-highlighting-advances-in-tumor-typing-therapy-selection-and-expanded-utility-of-multiomic-tissue-and-liquid-biopsy-testing-at-aacr-2026", "date": "2026-03-18", "summary": "Guardant Health and its collaborators will present 28 abstracts, including 3 oral sessions, at the AACR Annual Meeting in April 2026. The presentations will showcase advances in methylation-based tumor classification and liquid biopsy technology, highlighting the utility of Guardant360 Tissue and Guardant360 Liquid in tumor typing and therapy selection. Key data includes high accuracy of Guardant360 Tissue in determining tissue of origin and expanded clinical actionability of Guardant360 Liquid,", "sentiment_score": 0.476197, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "Blood tests flag new primary cancers and actionable results in AACR data", "url": "https://www.stocktitan.net/news/GH/guardant-health-to-present-28-abstracts-highlighting-advances-in-bapvicsrazan.html", "date": "2026-03-18", "summary": "Guardant Health will present 28 abstracts at the American Association for Cancer Research (AACR) Annual Meeting in April 2026, highlighting advances in its liquid biopsy technology. Key findings include the high accuracy of Guardant360 Tissue in determining cancer origin, the expanded utility of Guardant360 Liquid in identifying actionable findings for breast and colorectal cancer patients, and Guardant Reveal's potential to detect new primary malignancies during minimal residual disease monitor", "sentiment_score": 0.308783, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (NASDAQ:GH) CFO Sells $261,120.00 in Stock", "url": "https://www.marketbeat.com/instant-alerts/guardant-health-nasdaqgh-cfo-sells-26112000-in-stock-2026-03-17/", "date": "2026-03-18", "summary": "Guardant Health (NASDAQ:GH) CFO Michael Brian Bell sold 3,000 shares of the company's stock for $261,120.00 on March 16, 2026, reducing his stake by 6.44%. The company recently missed EPS expectations in its latest earnings report but exceeded revenue estimates. Guardant Health stock traded at $88.75 mid-day, below its 50-day and 200-day simple moving averages, and institutional investors own approximately 92.6% of the outstanding shares.", "sentiment_score": 0.037687, "sentiment_label": "Neutral", "relevance_score": 0.308771, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (NASDAQ: GH) CLO gains stock through RSU vesting", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-4dd8254703cb.html", "date": "2026-03-17", "summary": "Guardant Health's Chief Legal Officer, John G. Saia, acquired additional common stock through the vesting of performance-based and time-based Restricted Stock Units (RSUs) on March 15, 2026. After the transactions, and accounting for shares withheld for tax obligations, Mr. Saia directly owns 56,903 shares of Guardant Health common stock. The filing details how 4,622 shares were retained by the company at $85.49 per share to cover tax withholdings related to the RSU vesting.", "sentiment_score": 0.012519, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.34, "confidence": 0.34 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) director acquires 249 shares via RSU vesting", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-78f740c8c862.html", "date": "2026-03-17", "summary": "Guardant Health director Tariq Musa converted 249 restricted stock units (RSUs) into common stock on March 15, 2026, as part of a scheduled vesting. This transaction increased his direct holdings to 8,742 common shares, with an additional 2,999 RSUs remaining. The RSUs, granted on March 6, 2023, vest over four years, with 25% vesting on the first anniversary and the rest monthly over the subsequent three years.", "sentiment_score": 0.010349, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Survey Supports Blood Tests for Colorectal Cancer Screening", "url": "https://www.curetoday.com/view/survey-supports-blood-tests-for-colorectal-cancer-screening", "date": "2026-03-17", "summary": "A new national survey indicates that 92% of adults eligible for colorectal cancer screening believe blood-based tests should be widely accessible and covered by insurance. These tests could significantly increase screening participation, with 77% of respondents stating they would be less likely to delay screening if a blood test were available. The survey highlights that blood tests could serve as a crucial entry point to screening, potentially overcoming common barriers associated with traditio", "sentiment_score": 0.439769, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.44, "confidence": 0.44 } }, { "source": "alpha_vantage", "title": "Here’s Why Artisan Small Cap Fund Bets on Guardant Health (GH)", "url": "https://www.insidermonkey.com/blog/heres-why-artisan-small-cap-fund-bets-on-guardant-health-gh-1718418/", "date": "2026-03-17", "summary": "Artisan Small Cap Fund highlighted its new position in Guardant Health, Inc. (NASDAQ: GH) in its Q4 2025 investor letter. Guardant Health specializes in liquid biopsy diagnostics for cancer detection and monitoring. Despite the fund's investment, Insider Monkey suggests that some AI stocks offer greater potential for higher and faster returns than Guardant Health.", "sentiment_score": 0.423641, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health launches Shield Multi-Cancer Detection Test in APAC market", "url": "https://www.biospectrumasia.com/news/54/27363/guardant-health-launches-shield-multi-cancer-detection-test-in-apac-market.html", "date": "2026-03-17", "summary": "Guardant Health has launched its Shield multi-cancer detection (MCD) laboratory developed test (LDT) in key Asian markets including Hong Kong, Singapore, and the Philippines, starting April 2026. This blood test screens for 10 common cancers in average-risk individuals aged 45 or older. The initiative is supported by a partnership with Manulife, aiming to enhance early cancer detection access in the region.", "sentiment_score": 0.480101, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health launches multi-cancer blood test in Asia through Manulife partnership", "url": "https://mugglehead.com/guardant-health-launches-multi-cancer-blood-test-in-asia-through-manulife-partnership/", "date": "2026-03-17", "summary": "Guardant Health (NASDAQ: GH) has launched its Shield multi-cancer detection blood test in several Asian markets through a partnership with Manulife Financial Corporation (TSE: MFC). The test, aimed at individuals aged 45 and older, screens for 10 common cancers using a blood sample. This expansion into Hong Kong, Singapore, and the Philippines, starting in April 2026, aims to improve early cancer detection rates in regions where cancer remains a leading cause of death.", "sentiment_score": 0.470572, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Singapore's Guardant Health launches Shield Multi-Cancer Detection (MCD) Test in APAC market", "url": "https://www.biospectrumasia.com/news/26/27363/singaporesguardant-health-launches-shield-multi-cancer-detection-mcd-test-in-apac-market.html", "date": "2026-03-17", "summary": "Guardant Health has launched its Shield multi-cancer detection (MCD) test in several Asian markets including Hong Kong, Singapore, and the Philippines, starting April 2026. This blood test screens for 10 common cancers in individuals aged 45 or older and aims to enhance early detection and screening participation in the APAC region. The initiative includes a partnership with Manulife, marking a significant step in making innovative early cancer detection technologies accessible.", "sentiment_score": 0.618992, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Blood test that screens for 10 cancers to reach Manulife customers in Asia", "url": "https://www.stocktitan.net/news/GH/guardant-health-launches-shield-multi-cancer-detection-mcd-test-in-0eb8oecxpwvf.html", "date": "2026-03-16", "summary": "Guardant Health has launched its Shield multi-cancer detection (MCD) blood test in several Asian markets through a partnership with Manulife. This methylation-based test screens for 10 common cancer types in individuals aged 45 or older, with access for eligible Manulife customers in Hong Kong, Singapore, and the Philippines beginning in April 2026. The collaboration aims to expand early cancer detection in a region where cancer remains a leading cause of death.", "sentiment_score": 0.462814, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "alpha_vantage", "title": "Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership", "url": "https://finance.yahoo.com/news/guardant-health-launches-shield-multi-120500633.html", "date": "2026-03-16", "summary": "Guardant Health has partnered with Manulife to launch its Shield Multi-Cancer Detection (MCD) test in several Asian markets, including Hong Kong, Singapore, and the Philippines. This collaboration allows eligible Manulife customers to access the blood-based test, which screens for 10 common cancers in individuals aged 45 or older. The initiative aims to enhance early cancer detection efforts in a region where cancer remains a leading cause of death.", "sentiment_score": 0.454883, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "HighVista Strategies LLC Acquires 36,318 Shares of Guardant Health, Inc. $GH", "url": "https://www.marketbeat.com/instant-alerts/filing-highvista-strategies-llc-acquires-36318-shares-of-guardant-health-inc-gh-2026-03-16/", "date": "2026-03-16", "summary": "HighVista Strategies LLC significantly increased its stake in Guardant Health by 128.5% in the third quarter, acquiring 36,318 additional shares. Despite insiders selling over 20,000 shares, institutional investors now own 92.60% of the company's stock. Guardant Health missed EPS estimates but exceeded revenue expectations, and analysts maintain a \"Moderate Buy\" rating with an average target price of $122.57.", "sentiment_score": 0.141458, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Fred Alger Management LLC Has $39.89 Million Holdings in Guardant Health, Inc. $GH", "url": "https://www.marketbeat.com/instant-alerts/filing-fred-alger-management-llc-has-3989-million-holdings-in-guardant-health-inc-gh-2026-03-16/", "date": "2026-03-16", "summary": "Fred Alger Management LLC significantly increased its stake in Guardant Health, Inc. (NASDAQ:GH) by 70.9% in the third quarter, now owning 638,487 shares valued at $39.89 million. Despite beating revenue expectations, Guardant Health missed EPS estimates in its latest quarterly report. Analysts largely maintain a bullish outlook on the company, with an average price target of $122.57, though recent insider transactions show both sales and director ownership changes.", "sentiment_score": 0.225642, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.990517, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Is Guardant Health’s (GH) Shield Tour Redefining Its Competitive Moat in Cancer Screening?", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/is-guardant-healths-gh-shield-tour-redefining-its-competitiv", "date": "2026-03-16", "summary": "Guardant Health has launched its \"Shield Across America\" tour to expand the reach of its FDA-approved Shield blood test for colorectal cancer screening, targeting underserved areas and eligible adults. This initiative, supported by new NCCN guidelines and public payer coverage, aims to overcome screening barriers and increase test usage. While the tour reinforces Guardant's investment thesis, the company faces continued risks associated with high cash burn and the long path to profitability desp", "sentiment_score": 0.11971, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.572, "confidence": 0.57 } }, { "source": "alpha_vantage", "title": "Eventide Asset Management LLC Lowers Holdings in Guardant Health, Inc. $GH", "url": "https://www.marketbeat.com/instant-alerts/filing-eventide-asset-management-llc-lowers-holdings-in-guardant-health-inc-gh-2026-03-15/", "date": "2026-03-15", "summary": "Eventide Asset Management LLC reduced its stake in Guardant Health, Inc. (NASDAQ:GH) by 4.0% in the third quarter, though it remains its largest holding. Despite this reduction and insider selling, Wall Street analysts largely maintain a \"Moderate Buy\" rating with an average price target of $122.57. Guardant Health recently missed EPS expectations but saw strong revenue growth, with institutional investors owning a significant portion of its stock.", "sentiment_score": -0.133094, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "alpha_vantage", "title": "Cinctive Capital Management LP Buys Shares of 121,130 Guardant Health, Inc. $GH", "url": "https://www.marketbeat.com/instant-alerts/filing-cinctive-capital-management-lp-buys-shares-of-121130-guardant-health-inc-gh-2026-03-15/", "date": "2026-03-15", "summary": "Cinctive Capital Management LP acquired a new position of 121,130 shares in Guardant Health, Inc. (NASDAQ:GH) during the third quarter, valued at approximately $7.57 million. This purchase represents about 0.10% of Guardant Health's stock. Despite significant insider selling totaling $12.2 million in the last quarter, including a substantial sale by CEO Helmy Eltoukhy, the company reported Q4 revenue of $281.3 million, beating expectations with a 39.4% year-over-year increase, though EPS missed ", "sentiment_score": 0.140684, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) Valuation Check As Shield Across America Expands Colorectal Cancer Screening Reach", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-valuation-check-as-shield-across-america", "date": "2026-03-14", "summary": "Guardant Health (GH) recently launched \"Shield Across America,\" a mobile screening tour for its colorectal cancer blood test, Shield, amidst a 20.53% decline in its 30-day share price but a strong 99.32% 1-year return. Despite short-term price drops, the company's valuation narrative suggests it's 35.5% undervalued at $132.57 per share compared to its current $85.49, driven by significant regulatory and clinical milestones for Shield that promise future revenue growth. However, investors are cau", "sentiment_score": 0.429747, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.599, "confidence": 0.6 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) awards 17,040 RSUs to Chief People Officer Monroe", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-e69d05dc36b9.html", "date": "2026-03-14", "summary": "Guardant Health (GH) has granted 17,040 Restricted Stock Units (RSUs) to its Chief People Officer, Terilyn J. Monroe, on March 11, 2026. These RSUs are part of a routine equity compensation award, not an open-market transaction. The RSUs will vest over a three-year period, with 33% vesting on April 1, 2027, and the remainder vesting in equal quarterly installments over the subsequent two years.", "sentiment_score": 0.042766, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.459, "confidence": 0.46 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) CFO granted 26,582 RSUs vesting over three years", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-9f1ce93e851c.html", "date": "2026-03-14", "summary": "Guardant Health, Inc.'s CFO, Michael Brian Bell, was granted 26,582 Restricted Stock Units (RSUs) on March 11, 2026, as part of his equity compensation. These RSUs will vest over a three-year period, with 33% vesting on April 1, 2027, and the remaining 67% vesting in equal quarterly installments over the subsequent two years, contingent on continued service. This award is a compensation grant and not an open-market purchase.", "sentiment_score": 0.033399, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "alpha_vantage", "title": "KMI partners with Guardant Health on liquid biopsy cancer screening", "url": "https://www.koreaherald.com/article/10692886", "date": "2026-03-12", "summary": "The Korea Medical Institute (KMI) has signed a memorandum of understanding with US-based Guardant Health to collaborate on liquid biopsy-based precision cancer screening. This partnership aims to develop precision oncology services, including early cancer screening tests and genomic mutation analysis, and establish an integrated cancer management system. The collaboration seeks to enhance diagnostic accuracy and advance precision medicine in Korea.", "sentiment_score": 0.439765, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Quest Diagnostics Expands Preventive Reach With Shield Colorectal Blood Test", "url": "https://simplywall.st/stocks/us/healthcare/nyse-dgx/quest-diagnostics/news/quest-diagnostics-expands-preventive-reach-with-shield-color", "date": "2026-03-11", "summary": "Quest Diagnostics (NYSE:DGX) has partnered with Guardant Health to offer the FDA-approved Shield blood test for colorectal cancer screening, making it available nationwide through Quest’s testing network. This collaboration expands access to preventive care and adds a new product to Quest’s diagnostics menu. The article highlights that this move reinforces Quest's role in preventive testing and its broader push into oncology-related diagnostics, suggesting investors monitor clinical uptake, reim", "sentiment_score": 0.252231, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.851984, "sentiment": { "label": "positive", "score": 0.128, "confidence": 0.13 } }, { "source": "alpha_vantage", "title": "Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics", "url": "https://www.businesswire.com/news/home/20260310124738/en/Guardant-Healths-Shield-Blood-based-Screening-Test-for-Colorectal-Cancer-Now-Accessible-Through-National-Test-Ordering-and-Collection-Network-of-Quest-Diagnostics", "date": "2026-03-11", "summary": "Guardant Health's Shield blood-based colorectal cancer screening test is now accessible nationwide through Quest Diagnostics, significantly expanding its reach. This collaboration allows physicians to order Shield through their existing Quest accounts and utilize Quest’s extensive network for blood draws. The Shield test is FDA-approved, covered by Medicare and other networks, and aims to increase screening rates for colorectal cancer, a leading cause of cancer-related deaths.", "sentiment_score": 0.425928, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Hidalgo Medina sells Guardant Health (GH) shares for $118,996", "url": "https://www.investing.com/news/insider-trading-news/hidalgo-medina-sells-guardant-health-gh-shares-for-118996-93CH-4551066", "date": "2026-03-11", "summary": "Manuel Hidalgo Medina, a Director at Guardant Health, Inc. (NASDAQ:GH), sold 1,300 shares of the company's common stock for $118,996 on March 6, 2026, after exercising options for 1,000 shares. Although Guardant Health's stock has surged 154% in the past year, InvestingPro analysis indicates it is currently overvalued. This transaction follows recent positive developments for Guardant Health, including strong Q4 2025 results and increased price targets from several analysts, despite the stock's ", "sentiment_score": -0.141599, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health's Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics", "url": "https://nationaltoday.com/us/ca/palo-alto/news/2026/03/10/guardant-healths-shield-blood-based-screening-test-for-colorectal-cancer-now-accessible-through-national-test-ordering-and-collection-network-of-quest-diagnostics/", "date": "2026-03-10", "summary": "Guardant Health's Shield blood-based screening test for colorectal cancer is now accessible through Quest Diagnostics' national network. This partnership aims to increase screening rates for colorectal cancer, the second leading cause of cancer-related deaths in the U.S., by offering a convenient, FDA-approved blood test. The collaboration leverages Quest's extensive infrastructure, including its patient service centers and connectivity with nearly 650,000 clinician accounts, to make the Shield ", "sentiment_score": 0.00293, "sentiment_label": "Neutral", "relevance_score": 0.304445, "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Hidalgo Medina sells Guardant Health (GH) shares for $118,996", "url": "https://m.investing.com/news/insider-trading-news/hidalgo-medina-sells-guardant-health-gh-shares-for-118996-93CH-4551066?ampMode=1", "date": "2026-03-10", "summary": "Director Manuel Hidalgo Medina of Guardant Health (NASDAQ:GH) sold 1,300 shares of common stock for $118,996 and exercised options for 1,000 shares for $32,549. This comes amidst recent positive analyst revisions for Guardant Health, including raised price targets from Canaccord Genuity and Stifel, and new coverage from Baird with an Outperform rating. The company also reported strong Q4 2025 Shield product revenue and published a study on its ctDNA blood test for colon cancer recurrence.", "sentiment_score": 0.141213, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) director sells 1,300 shares after option exercise", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-21e9c9c13f2e.html", "date": "2026-03-10", "summary": "Guardant Health director Manuel Hidalgo Medina reported exercising options for 1,000 shares and subsequently selling 1,300 common shares in open-market transactions on March 6, 2026. The option exercise was at $0.00 per share, with the common shares sold at average prices of $91.6065 and $91.3001. After these transactions, Medina directly holds 1,193 Guardant Health common shares.", "sentiment_score": -0.259979, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health’s Shield Tour Links Rural Access And Growth Expectations", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-healths-shield-tour-links-rural-access-and-growth-e/amp", "date": "2026-03-07", "summary": "Guardant Health has launched its \"Shield Across America\" mobile tour to bring its FDA-approved Shield blood test for colorectal cancer screening to over 100 underserved rural communities. This initiative, aligning with National Colorectal Cancer Awareness Month, aims to boost screening rates by offering a convenient blood-based alternative to colonoscopies, directly engaging patients and healthcare providers. While accelerating adoption and revenue growth, investors should consider the financial", "sentiment_score": 0.251012, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "Guardant Health’s Shield Tour Links Rural Access And Growth Expectations", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-healths-shield-tour-links-rural-access-and-growth-e", "date": "2026-03-07", "summary": "Guardant Health has launched its Shield Across America mobile tour to bring its FDA-approved Shield blood test for colorectal cancer screening to over 100 underserved rural communities. This initiative, coinciding with National Colorectal Cancer Awareness Month, highlights the company's effort to increase adoption of its convenient blood-based screening option. While the tour addresses a critical public health need and could boost test utilization, investors should consider the company's unprofi", "sentiment_score": 0.233643, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.98621, "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened", "url": "https://www.businesswire.com/news/home/20260303627930/en/Actor-and-Cancer-Advocate-Patrick-Dempsey-Partners-with-Guardant-Health-to-Raise-Awareness-about-Colorectal-Cancer-Screening-and-Shield-Blood-Test-Sharing-His-Experience-Getting-Screened", "date": "2026-03-07", "summary": "Actor and cancer advocate Patrick Dempsey has partnered with Guardant Health to raise awareness about colorectal cancer (CRC) screening, particularly highlighting the FDA-approved Shield blood test. Motivated by his mother's cancer fight, Dempsey shared his own experience getting screened with Shield, emphasizing its convenience as a blood test for individuals aged 45 and over at average risk for CRC. This collaboration aims to encourage early detection of CRC, which remains a leading cause of c", "sentiment_score": 0.476809, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.791, "confidence": 0.79 } }, { "source": "alpha_vantage", "title": "Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America", "url": "https://www.businesswire.com/news/home/20260304217437/en/Guardant-Health-Launches-Coast-to-Coast-Screening-Tour-Bringing-Shield-Colon-Cancer-Blood-Test-to-Over-100-Communities-Across-America", "date": "2026-03-06", "summary": "Guardant Health has launched a coast-to-coast screening tour to bring its Shield colon cancer blood test to over 100 communities across America. This initiative aims to improve access to colon cancer screening and raise awareness about the importance of early detection, particularly for individuals aged 45 and older. The tour will highlight the convenience and non-invasive nature of the Guardant Shield test, which can be done from home.", "sentiment_score": 0.423525, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41895789", "title": "Comparison of tissue acquisition techniques for Next-Generation Sequencing of non-small cell lung cancer (NSCLC).", "authors": "Bhamani A et al.", "journal": "BMJ open respiratory research", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41895789/", "sentiment": { "label": "negative", "score": -0.46, "confidence": 0.46 } }, { "source": "pubmed", "pmid": "41895314", "title": "Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration.", "authors": "Dingemans AC et al.", "journal": "The Lancet. Respiratory medicine", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41895314/", "sentiment": { "label": "negative", "score": -0.869, "confidence": 0.87 } }, { "source": "pubmed", "pmid": "41883872", "title": "Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer.", "authors": "Qadri F et al.", "journal": "Therapeutic advances in medical oncology", "date": "2026-03-28", "url": "https://pubmed.ncbi.nlm.nih.gov/41883872/", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41882405", "title": "Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.", "authors": "Park W et al.", "journal": "Nature medicine", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41882405/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41880871", "title": "Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).", "authors": "Kito Y et al.", "journal": "European journal of cancer (Oxford, England : 1990)", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41880871/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41876649", "title": "AI-based chest X-ray prioritization in the lung cancer diagnostic pathway: the LungIMPACT randomized controlled trial.", "authors": "Woznitza N et al.", "journal": "Nature medicine", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41876649/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41874648", "title": "Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).", "authors": "Mollica V et al.", "journal": "Cancer immunology, immunotherapy : CII", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874648/", "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "pubmed", "pmid": "41872602", "title": "Implementation of the NHS England Lung Cancer Screening Programme over 5 years.", "authors": "Lee RW et al.", "journal": "Nature medicine", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41872602/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41871874", "title": "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.", "authors": "McKay RR et al.", "journal": "Journal for immunotherapy of cancer", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41871874/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41870735", "title": "Efficacy and safety of trastuzumab biosimilar CT-P6 plus SOX or CapeOX in HER2-positive advanced gastric cancer: a multicenter phase II KSCC-TROX study.", "authors": "Oki E et al.", "journal": "Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41870735/", "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "pubmed", "pmid": "41866411", "title": "Efficacy and safety of peptide radionuclide therapy with (177)Lu-DOTATATE in Japanese patients with advanced neuroendocrine neoplasm: a multicenter retrospective study (JON2203-N).", "authors": "Okamoto K et al.", "journal": "Journal of gastroenterology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41866411/", "sentiment": { "label": "positive", "score": 0.586, "confidence": 0.59 } }, { "source": "pubmed", "pmid": "41864749", "title": "Survival outcome of VATS compared with open lobectomy for lung cancer: an individual patient data meta-analysis of randomised trials.", "authors": "Harris RA et al.", "journal": "Lancet (London, England)", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41864749/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41861751", "title": "Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia.", "authors": "Rugo HS et al.", "journal": "ESMO open", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41861751/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41861516", "title": "Multidisciplinary international expert consensus recommendations on tissue acquisition in non-small cell lung cancer.", "authors": "Lee P et al.", "journal": "EBioMedicine", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41861516/", "sentiment": { "label": "negative", "score": -0.46, "confidence": 0.46 } }, { "source": "pubmed", "pmid": "41853813", "title": "Durable disease control in a radiation-induced high-grade glioma harboring NF1 and PTPN11 co-mutations.", "authors": "Sherief M et al.", "journal": "Neuro-oncology advances", "date": "2026 Jan-D", "url": "https://pubmed.ncbi.nlm.nih.gov/41853813/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41851476", "title": "Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study.", "authors": "Shore ND et al.", "journal": "Prostate cancer and prostatic diseases", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41851476/", "sentiment": { "label": "negative", "score": -0.751, "confidence": 0.75 } }, { "source": "pubmed", "pmid": "41849281", "title": "Implementing a successful patient navigation program for follow-up colonoscopy: Lessons from the PRECISE study.", "authors": "Thompson JH et al.", "journal": "PloS one", "date": "2026-03-28", "url": "https://pubmed.ncbi.nlm.nih.gov/41849281/", "sentiment": { "label": "positive", "score": 0.586, "confidence": 0.59 } }, { "source": "pubmed", "pmid": "41843267", "title": "SEOM-TTCC clinical guidelines for the treatment of head and neck cancer (2025).", "authors": "Arrazubi V et al.", "journal": "Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41843267/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41840238", "title": "First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.", "authors": "Shitara K et al.", "journal": "Nature medicine", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41840238/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41832914", "title": "Impact of peritoneal metastasis on overall survival in patients with advanced endometrial cancer receiving lenvatinib plus pembrolizumab.", "authors": "Boku S et al.", "journal": "Discover oncology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41832914/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41825704", "title": "Coupled-enzyme assay for MTAP activity in biological samples.", "authors": "Gilaj N et al.", "journal": "Analytical biochemistry", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41825704/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41825178", "title": "Increased detection of NRG1 fusions in non-squamous non-small cell lung cancer using combined DNA and RNA sequencing in a real-world cohort.", "authors": "Araújo BJ et al.", "journal": "Lung cancer (Amsterdam, Netherlands)", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41825178/", "sentiment": { "label": "negative", "score": -0.511, "confidence": 0.51 } }, { "source": "pubmed", "pmid": "41819545", "title": "Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609).", "authors": "Chae YK et al.", "journal": "Journal for immunotherapy of cancer", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41819545/", "sentiment": { "label": "negative", "score": -0.44, "confidence": 0.44 } }, { "source": "pubmed", "pmid": "41819104", "title": "Cell-type-specific transposon demethylation and TAD remodeling in aging mouse brain.", "authors": "Zeng Q et al.", "journal": "Cell", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41819104/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41817930", "title": "ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.", "authors": "Kuemmel S et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41817930/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41810446", "title": "Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars.", "authors": "Moura CS et al.", "journal": "World journal of gastroenterology", "date": "2026 Mar 7", "url": "https://pubmed.ncbi.nlm.nih.gov/41810446/", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "pubmed", "pmid": "41809806", "title": "Immunotherapy in metastatic castration-resistant prostate cancer: transformative for the few, not for all.", "authors": "de Souza VPB et al.", "journal": "Translational andrology and urology", "date": "2026 Feb 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41809806/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41809424", "title": "Bridging paradigms and shaping the future of resectable gastric cancer: a narrative review of the post-MATTERHORN era.", "authors": "Okemoto D et al.", "journal": "Gastroenterology report", "date": "2026-03-28", "url": "https://pubmed.ncbi.nlm.nih.gov/41809424/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41808570", "title": "Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy.", "authors": "Gandara DR et al.", "journal": "Cancer", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41808570/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41808091", "title": "Recovery from fulminant immune-related myocarditis induced by ipilimumab plus nivolumab in malignant pleural mesothelioma: a case report.", "authors": "Konya Y et al.", "journal": "BMC pulmonary medicine", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41808091/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41807638", "title": "Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics.", "authors": "Choo J et al.", "journal": "Nature reviews. Clinical oncology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41807638/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41798167", "title": "Acquired ERBB2 Amplification and Overexpression as On-Target Resistance Mechanisms to Zongertinib With Subsequent Response to Trastuzumab-Deruxtecan: A Case Report.", "authors": "McMahon DJ et al.", "journal": "JTO clinical and research reports", "date": "2026-03-28", "url": "https://pubmed.ncbi.nlm.nih.gov/41798167/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41796056", "title": "Review of Existing Approaches and Potential Role of Pharmacometrics in the Interpretation of Prognostic Circulating Serum Biomarkers in Advanced NSCLC.", "authors": "Ojara FW et al.", "journal": "Clinical and translational science", "date": "2026-03-28", "url": "https://pubmed.ncbi.nlm.nih.gov/41796056/", "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "pubmed", "pmid": "41793510", "title": "A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis.", "authors": "Giordano A et al.", "journal": "Breast cancer research and treatment", "date": "2026 Mar 7", "url": "https://pubmed.ncbi.nlm.nih.gov/41793510/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41792532", "title": "Ensuring High-Quality Rectal Cancer Surgery in an Era of Increasing Treatment Complexity.", "authors": "Brown KGM et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 6", "url": "https://pubmed.ncbi.nlm.nih.gov/41792532/", "sentiment": { "label": "negative", "score": -0.511, "confidence": 0.51 } }, { "source": "pubmed", "pmid": "41790338", "title": "Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI).", "authors": "Shibuki T et al.", "journal": "International journal of clinical oncology", "date": "2026 Mar 6", "url": "https://pubmed.ncbi.nlm.nih.gov/41790338/", "sentiment": { "label": "positive", "score": 0.477, "confidence": 0.48 } }, { "source": "pubmed", "pmid": "41785668", "title": "Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials.", "authors": "Jhaveri K et al.", "journal": "ESMO open", "date": "2026-03-28", "url": "https://pubmed.ncbi.nlm.nih.gov/41785668/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41783745", "title": "Potential Immune Microenvironment Biomarkers in SCLC: J-TAIL-2 Observational Study.", "authors": "Shirasawa M et al.", "journal": "JTO clinical and research reports", "date": "2026-03-28", "url": "https://pubmed.ncbi.nlm.nih.gov/41783745/", "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41781623", "title": "Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.", "authors": "Safonov A et al.", "journal": "Nature", "date": "2026 Mar 4", "url": "https://pubmed.ncbi.nlm.nih.gov/41781623/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41780642", "title": "Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease.", "authors": "Curigliano G et al.", "journal": "Annals of oncology : official journal of the European Society for Medical Oncology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41780642/", "sentiment": { "label": "negative", "score": -0.823, "confidence": 0.82 } }, { "source": "pubmed", "pmid": "41779341", "title": "Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.", "authors": "Kawagoe R et al.", "journal": "International journal of clinical oncology", "date": "2026 Mar 4", "url": "https://pubmed.ncbi.nlm.nih.gov/41779341/", "sentiment": { "label": "negative", "score": -0.869, "confidence": 0.87 } }, { "source": "pubmed", "pmid": "41778251", "title": "Development of Second Primary Malignancies in Long-term Survivors of Unresectable Esophageal Cancer.", "authors": "Watanabe R et al.", "journal": "Cancer diagnosis & prognosis", "date": "2026 Mar-A", "url": "https://pubmed.ncbi.nlm.nih.gov/41778251/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41772242", "title": "ASO Visual Abstract: Incidence and Predictors of Neoplastic Diagnosis in Patients with a Clinically Abnormal Appendix.", "authors": "Gowda T et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41772242/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41768274", "title": "Development and validation of a generalisable machine learning algorithm for identifying interstitial lung disease cohorts: a retrospective cohort study.", "authors": "Farrand E et al.", "journal": "EClinicalMedicine", "date": "2026-03-28", "url": "https://pubmed.ncbi.nlm.nih.gov/41768274/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41764032", "title": "Impact of offering blood-based testing alongside existing modalities for colorectal cancer screening among those who previously declined screening: an economic evaluation.", "authors": "Forbes SP et al.", "journal": "Journal of medical economics", "date": "2026-03-28", "url": "https://pubmed.ncbi.nlm.nih.gov/41764032/", "sentiment": { "label": "negative", "score": -0.86, "confidence": 0.86 } }, { "source": "pubmed", "pmid": "41761743", "title": "Multiomic characterization of small cell lung cancer: Real-world insights into therapeutic opportunities.", "authors": "Puri S et al.", "journal": "Cancer", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41761743/", "sentiment": { "label": "negative", "score": -0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41761577", "title": "Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF‑mutated metastatic colorectal cancer: the BEETS (JACCRO CC‑18) study.", "authors": "Kotani D et al.", "journal": "The oncologist", "date": "2026 Mar 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41761577/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41748929", "title": "Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer.", "authors": "Sahin IH et al.", "journal": "NPJ precision oncology", "date": "2026 Feb 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41748929/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41748568", "title": "Tumor-informed circulating tumor DNA stratifies recurrence risk and survival in anal squamous cell carcinoma.", "authors": "Romesser PB et al.", "journal": "Nature communications", "date": "2026 Feb 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41748568/", "sentiment": { "label": "negative", "score": -0.572, "confidence": 0.57 } }, { "source": "pubmed", "pmid": "41747585", "title": "Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma.", "authors": "Shitara K et al.", "journal": "ESMO open", "date": "2026-03-28", "url": "https://pubmed.ncbi.nlm.nih.gov/41747585/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "getagraph", "title": "Buy Signal Guardant Health Inc - 3 Mar 2026 @ 15:35 -> USD93.91", "text": "Ticker: **GH**\n\nExchange: **NASDAQ**\n\nTime: **3 Mar 2026 @ 15:35**\n\nPrice: **USD93.91**\n\nLink: https://getagraph.com/NASDAQ/stock/live-signals/GH/ENG", "author": "jvc72", "score": 1, "num_comments": 0, "date": "2026-03-03", "url": "https://reddit.com/r/getagraph/comments/1rk0rxn/buy_signal_guardant_health_inc_3_mar_2026_1535/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "DeepFuckingValue", "title": "After-Hours Gainers and Losers for Today (March 24, 2026) 📈 📉", "text": "Here are today's top after-hours performers showing the biggest moves after regular trading hours.\n\n## 📈 After-Hours Gainers:\n\n| Symbol | Company | After-Hours | Regular Hours | Change | %Change |\n|:-------|:--------|:----------:|:-------------:|:------:|:-------:|\n| [ARM](https://marketrodeo.com/asset/ARM) | Arm Holdings plc American Depositary Shares | 144.76 | 134.96 | +9.80 | +7.26% |\n| [LTM](https://marketrodeo.com/asset/LTM) | LATAM Airlines Group S.A. | 51.50 | 49.03 | +2.47 | +5.04% |\n| ", "author": "MarketRodeo", "score": 3, "num_comments": 0, "date": "2026-03-24", "url": "https://reddit.com/r/DeepFuckingValue/comments/1s2qaha/afterhours_gainers_and_losers_for_today_march_24/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "reddit", "subreddit": "DeepFuckingValue", "title": "After-Hours Gainers and Losers for Today (March 13, 2026) 📈 📉", "text": "Here are today's top after-hours performers showing the biggest moves after regular trading hours.\n\n## 📈 After-Hours Gainers:\n\n| Symbol | Company | After-Hours | Regular Hours | Change | %Change |\n|:-------|:--------|:----------:|:-------------:|:------:|:-------:|\n| [CHKP](https://marketrodeo.com/asset/CHKP) | Check Point Software Technologies Ltd. | 181.23 | 153.65 | +27.58 | +17.95% |\n| [STLD](https://marketrodeo.com/asset/STLD) | Steel Dynamics, Inc. | 199.24 | 170.60 | +28.64 | +16.79% |\n| ", "author": "MarketRodeo", "score": 3, "num_comments": 1, "date": "2026-03-13", "url": "https://reddit.com/r/DeepFuckingValue/comments/1rszlgw/afterhours_gainers_and_losers_for_today_march_13/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "reddit", "subreddit": "Swing_Trader_Trading", "title": "Middle East war begins – stocks drop – Update 03/09/26", "text": "[Blog Post:](https://positiontrader.blog/2026/03/09/middle-east-war-begins-stocks-drop-update-03-09-26/)\n\nhttps://preview.redd.it/kf19dhculjng1.png?width=877&format=png&auto=webp&s=5f11966e2029af18cd9e91fec37a0655543a614d\n\n* [**Quant 30** ](https://positiontrader.blog/2026/03/09/middle-east-war-begins-stocks-drop-update-03-09-26/#portfolio)**– Up over 26% since June 2025**\n* **Quant Weekly – Up over 27% since June** **2025**\n* **Legacy – Up over 270% since April 2023**\n* [**Education** ](https:/", "author": "Swing_Trader_Trading", "score": 2, "num_comments": 1, "date": "2026-03-09", "url": "https://reddit.com/r/Swing_Trader_Trading/comments/1roycq7/middle_east_war_begins_stocks_drop_update_030926/", "sentiment": { "label": "negative", "score": -0.718, "confidence": 0.72 } }, { "source": "reddit", "subreddit": "Swing_Trader_Trading", "title": "Extreme fear grips the stock market – stock drop slows – Update 03/16/26", "text": "[Blog Post:](https://positiontrader.blog/2026/03/16/extreme-fear-grips-the-stock-market-stock-drop-slows-update-03-16-26/)\n\nhttps://preview.redd.it/ol6riok5g2pg1.png?width=1793&format=png&auto=webp&s=5d0155bc6fd0f1b0fafa9d68bccc95c29c00823d\n\n* [**Quant 30** ](https://positiontrader.blog/2026/03/16/extreme-fear-grips-the-stock-market-stock-drop-slows-update-03-16-26/#portfolio)**– Up over 24% since June 2025**\n* **Quant Weekly – Up over 26% since June** **2025**\n* **Legacy – Up over 270% since Ap", "author": "Swing_Trader_Trading", "score": 2, "num_comments": 0, "date": "2026-03-16", "url": "https://reddit.com/r/Swing_Trader_Trading/comments/1rv7j7d/extreme_fear_grips_the_stock_market_stock_drop/", "sentiment": { "label": "negative", "score": -0.68, "confidence": 0.68 } }, { "source": "reddit", "subreddit": "EverHint", "title": "EverHint – SMA20 × SMA50 Crossover – Top 10 Buy and Top 10 Sell Signals for Feb 25, 2026", "text": "## What This Signal Is (Quick)\n\nThis strategy detects **fresh crossovers** between the 20-day simple moving average (SMA20) and the 50-day simple moving average (SMA50):\n\n * **Buy Signal (SMA20_x_SMA50_Buy) - \"Golden Cross\"** : SMA(20) crosses **above** SMA(50) on today's close\n\n * Short-term momentum (20 days) exceeds medium-term trend (50 days)\n * Bullish trend confirmation with high reliability\n * Ideal for medium-term trend following (4-12 week holding periods)\n * **Sell Signal (S", "author": "Mamuthone125", "score": 1, "num_comments": 0, "date": "2026-02-26", "url": "https://reddit.com/r/EverHint/comments/1rf31xr/everhint_sma20_sma50_crossover_top_10_buy_and_top/", "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "reddit", "subreddit": "Quantisnow", "title": "Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data", "text": "", "author": "Quantisnow", "score": 1, "num_comments": 0, "date": "2026-03-24", "url": "https://reddit.com/r/Quantisnow/comments/1s2dj2p/verana_health_and_guardant_health_partner_to/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "RWATimes", "title": "Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection ...", "text": "![](https://mms.businesswire.com/media/20260318529389/en/1330243/22/GuardantHealthLogo_TM_RGB-2C.jpg)\n\n-Guardant Reveal demonstrates expanded utility in identifying new, primary cancers during minimal residual disease (MRD) monitoringStudies show strong performance of Guardant360 Tissue in determining ...\n\n **Details:**\n- **Published:** 18/03/2026 12:05 (UTC)\n- **📊 Characteristics Score:**\n > **Asset Type:** *others*\n > **Sentiment:** `0.3`\n > **Entropy:** `0.75`\n > **Relevance:** `0.9`\n >", "author": "rwatimes", "score": 1, "num_comments": 0, "date": "2026-03-22", "url": "https://reddit.com/r/RWATimes/comments/1s0dfot/guardant_health_to_present_28_abstracts/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "reddit", "subreddit": "Quantisnow", "title": "Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026", "text": "", "author": "Quantisnow", "score": 1, "num_comments": 0, "date": "2026-03-18", "url": "https://reddit.com/r/Quantisnow/comments/1rx23dm/guardant_health_to_present_28_abstracts/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "reddit", "subreddit": "Quantisnow", "title": "Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership", "text": "", "author": "Quantisnow", "score": 1, "num_comments": 0, "date": "2026-03-16", "url": "https://reddit.com/r/Quantisnow/comments/1rv7mrt/guardant_health_launches_shield_multicancer/", "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "reddit", "subreddit": "Quantisnow", "title": "New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare", "text": "", "author": "Quantisnow", "score": 2, "num_comments": 0, "date": "2026-03-13", "url": "https://reddit.com/r/Quantisnow/comments/1rsljb0/new_guardant_healthharris_poll_survey_shows_92_of/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "reddit", "subreddit": "Quantisnow", "title": "Guardant Health's Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics", "text": "", "author": "Quantisnow", "score": 2, "num_comments": 0, "date": "2026-03-10", "url": "https://reddit.com/r/Quantisnow/comments/1rpv5qg/guardant_healths_shield_bloodbased_screening_test/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "reddit", "subreddit": "Penny_Stock_USA", "title": "Guardant’s new Shield screening tour shows blood-based testing is moving into real-world rollout", "text": "https://preview.redd.it/c09uxs4b52ng1.png?width=315&format=png&auto=webp&s=265801915d05560931fe4bd597ec820cbe50a057\n\nToday Guardant Health launched \"Shield Across America\", a coast-to-coast mobile screening tour that will bring its Shield colorectal cancer blood test to over 100 U.S. communities, with a stated focus on rural areas that have low screening rates and higher CRC incidence and mortality.\n\nGuardant is tying the rollout to real-world completion behavior, citing 93% patient adherence in", "author": "UnlicensedWizard78", "score": 2, "num_comments": 0, "date": "2026-03-04", "url": "https://reddit.com/r/Penny_Stock_USA/comments/1rkqiwn/guardants_new_shield_screening_tour_shows/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "Quantisnow", "title": "Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America", "text": "", "author": "Quantisnow", "score": 1, "num_comments": 0, "date": "2026-03-04", "url": "https://reddit.com/r/Quantisnow/comments/1rkjntr/guardant_health_launches_coasttocoast_screening/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "reddit", "subreddit": "Quantisnow", "title": "Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened", "text": "", "author": "Quantisnow", "score": 1, "num_comments": 0, "date": "2026-03-03", "url": "https://reddit.com/r/Quantisnow/comments/1rjnjjd/actor_and_cancer_advocate_patrick_dempsey/", "sentiment": { "label": "negative", "score": -0.791, "confidence": 0.79 } }, { "source": "reddit", "subreddit": "Quantisnow", "title": "Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "text": "", "author": "Quantisnow", "score": 1, "num_comments": 0, "date": "2026-02-27", "url": "https://reddit.com/r/Quantisnow/comments/1rgiygf/guardant_health_announces_inducement_grants_under/", "sentiment": { "label": "positive", "score": 0.226, "confidence": 0.23 } }, { "source": "reddit", "subreddit": "heraldry", "title": "After a year, I'm ready for critiques!", "text": "Hello all! I started work on my assumed coat of arms this time last year, as trying to find if my Scottish ancestors possessed a COA was futile.\n\nAfter much research, deep contemplation, and countless edits, I think I finally have it right, and wishing for public opinion. I am open for your critiques! Before applying to and paying the $395 fee to the American College of Heraldry, as well as registering with the New England Committee on Heraldry, may I have your professional opinion and revi", "author": "EccentricArchivist", "score": 0, "num_comments": 17, "date": "2026-03-15", "url": "https://reddit.com/r/heraldry/comments/1ru63q2/after_a_year_im_ready_for_critiques/", "sentiment": { "label": "positive", "score": 0.42, "confidence": 0.42 } }, { "source": "reddit", "subreddit": "exactsciences", "title": "Exact Sciences Is Now Abbott!", "text": "As result of the Merger, on March 23, 2026, a change in control of Exact occurred, and Exact is now a direct, wholly owned subsidiary of Abbott Laboratories \n\nIt has been one heckuva run for long-time Exact Sciences shareholders! \n\nA roller coaster ride for sure at times. But always, for me at least, more than just an investment, but about being a part of the Company's mission to eradicate cancer and alleviate human suffering.\n\nAnd so many memories! \n\nWho can forget the fiasco in 2015, when Colo", "author": "Superchief440", "score": 13, "num_comments": 14, "date": "2026-03-23", "url": "https://reddit.com/r/exactsciences/comments/1s1mbwy/exact_sciences_is_now_abbott/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "heraldry", "title": "Remade personal arms after last post", "text": "I wanted to make a coat of arms for my house, where I have rescued a lot of cats and dogs, which led to my online handle ''The Cat Fortress'' \n\nI wanted to incorporate green as it is my favorite color and the overall color palette accidentally (but fortuitously) reflects the colors of my country, Brazil\n\nFor the crest I went with a white cat with blue eyes to represent one of the nicest, best cats I've rescued, A white flamepoint named Brie which is an elderly cat\n\nwould you help me blazon this ", "author": "thecatfortress", "score": 51, "num_comments": 8, "date": "2026-03-24", "url": "https://reddit.com/r/heraldry/comments/1s2g5oz/remade_personal_arms_after_last_post/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "heraldry", "title": "How to blazon properly/order of words", "text": "This is a prototype of my arms, I have some tweaks to make of shades of colors, but they'll stay the same. \n\n \nI understand the components of it, but am confused on the order. I know its a field of argent, a beaver rampant proper, (how do you say holding) a key or, and then idk how to say on a azure Chevron, with a crest of a cat sejant argent)", "author": "Cadet-Cryyx", "score": 7, "num_comments": 7, "date": "2026-03-25", "url": "https://reddit.com/r/heraldry/comments/1s3cig9/how_to_blazon_properlyorder_of_words/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "heraldry", "title": "Book Suggestions on Heraldry..", "text": "Hi everybody, im collecting books on heraldry as much as find anywhere but most of them old editions with b&w editions which doesnt bring any good to comprehend the essence at all.\n\nRecently came across with [this one](https://www.amazon.com/Illustrated-Book-Heraldry-International-Contemporary/dp/0754834603/) (see the second pic and continuous ones) *Lorenz Books Publishing by Stephen Slater*. And seems pretty comprehensive. What do you think about it? Do you have any other suggestions?\n\nThank y", "author": "lastmonday07", "score": 32, "num_comments": 5, "date": "2026-03-18", "url": "https://reddit.com/r/heraldry/comments/1rxe188/book_suggestions_on_heraldry/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "lungcancer", "title": "Bio marker testing", "text": "Hi \n\nMy mom 56F Asian with multiple pulmonary nodules was diagnosed with non small cell lung cancer. She is a non smoker. There is a high chance this is due to a mutation as per the pulmonologist. The oncologist that we are about to meet has sent the tissue and liquid biopsy to Caris. I have only heard of foundation one and guardant for lung cancer. Is Caris a good place to get biomarker testing done for lung cancer? Any insights or experiences with this company? ", "author": "Kind-Shake-953", "score": 9, "num_comments": 7, "date": "2026-03-14", "url": "https://reddit.com/r/lungcancer/comments/1rty5xk/bio_marker_testing/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "heraldry", "title": "Revised", "text": "So I got hammered pretty hard on my last post lol, my apologies for not doing more research before jumping in, I've taken the advice on board and hopefully there are fewer issues with this one", "author": "Party_Sandwich_232", "score": 12, "num_comments": 2, "date": "2026-03-27", "url": "https://reddit.com/r/heraldry/comments/1s5hins/revised/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "breastcancer", "title": "Reoccurrence?", "text": "Hi there awesome community!\n\nI’m 40 now with TCHP chemo, DMX, radiation and the exchange surgery completed in 2024. My doc has been doing regular Guardant tests and in August was the last negative result. The December one showed ctDNA at under 0.05% and bloodwork now shows my CA27.29 marker at 20 vs 10 in december (still in the green and only over 38 is it considered reason for stress).\n\nMy oncologist said they won’t take any action such as tests until the cancer marker is higher in bloodowrk or", "author": "AnnaMariaaaaaaa", "score": 4, "num_comments": 4, "date": "2026-03-12", "url": "https://reddit.com/r/breastcancer/comments/1rs6bfd/reoccurrence/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "HebelnMitKopf", "title": "ARK(K) am Freitag viel verkauft für 240 Mio--- nur Figma gekauft---", "text": "", "author": "Superb-Neck-5160", "score": 5, "num_comments": 2, "date": "2026-03-23", "url": "https://reddit.com/r/HebelnMitKopf/comments/1s1bfps/arkk_am_freitag_viel_verkauft_für_240_mio_nur/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } } ] } }